Transient hair loss in patients with chronic spontaneous urticaria treated with omalizumab

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Transient hair loss in patients with chronic spontaneous urticaria treated with omalizumab. / Noshela Ghazanfar, M; Thomsen, S F.

I: European Annals of Allergy and Clinical Immunology, Bind 49, Nr. 6, 11.2017, s. 284-285.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Noshela Ghazanfar, M & Thomsen, SF 2017, 'Transient hair loss in patients with chronic spontaneous urticaria treated with omalizumab', European Annals of Allergy and Clinical Immunology, bind 49, nr. 6, s. 284-285. https://doi.org/10.23822/EurAnnACI.1764-1489.08

APA

Noshela Ghazanfar, M., & Thomsen, S. F. (2017). Transient hair loss in patients with chronic spontaneous urticaria treated with omalizumab. European Annals of Allergy and Clinical Immunology, 49(6), 284-285. https://doi.org/10.23822/EurAnnACI.1764-1489.08

Vancouver

Noshela Ghazanfar M, Thomsen SF. Transient hair loss in patients with chronic spontaneous urticaria treated with omalizumab. European Annals of Allergy and Clinical Immunology. 2017 nov;49(6):284-285. https://doi.org/10.23822/EurAnnACI.1764-1489.08

Author

Noshela Ghazanfar, M ; Thomsen, S F. / Transient hair loss in patients with chronic spontaneous urticaria treated with omalizumab. I: European Annals of Allergy and Clinical Immunology. 2017 ; Bind 49, Nr. 6. s. 284-285.

Bibtex

@article{1f7110adf40942dabd72ff37eddb52a3,
title = "Transient hair loss in patients with chronic spontaneous urticaria treated with omalizumab",
abstract = "Summary: Omalizumab (anti-IgE) is used as add-on therapy for antihistamine refractory chronic urticaria patients. The most commonly reported adverse effects were headache, arthralgia, upper respiratory infections, fatigue, nausea and injection-site reactions. However, lately a few cases of hair loss have been reported. We describe a case of transient hair loss in a young female patient after initiating treatment with omalizumab. Despite this side effect, the patient continued with omalizumab treatment for 10 months with good effect.",
author = "{Noshela Ghazanfar}, M and Thomsen, {S F}",
year = "2017",
month = "11",
doi = "10.23822/EurAnnACI.1764-1489.08",
language = "English",
volume = "49",
pages = "284--285",
journal = "European Annals of Allergy and Clinical Immunology",
issn = "1764-1489",
publisher = "Meditions Carline",
number = "6",

}

RIS

TY - JOUR

T1 - Transient hair loss in patients with chronic spontaneous urticaria treated with omalizumab

AU - Noshela Ghazanfar, M

AU - Thomsen, S F

PY - 2017/11

Y1 - 2017/11

N2 - Summary: Omalizumab (anti-IgE) is used as add-on therapy for antihistamine refractory chronic urticaria patients. The most commonly reported adverse effects were headache, arthralgia, upper respiratory infections, fatigue, nausea and injection-site reactions. However, lately a few cases of hair loss have been reported. We describe a case of transient hair loss in a young female patient after initiating treatment with omalizumab. Despite this side effect, the patient continued with omalizumab treatment for 10 months with good effect.

AB - Summary: Omalizumab (anti-IgE) is used as add-on therapy for antihistamine refractory chronic urticaria patients. The most commonly reported adverse effects were headache, arthralgia, upper respiratory infections, fatigue, nausea and injection-site reactions. However, lately a few cases of hair loss have been reported. We describe a case of transient hair loss in a young female patient after initiating treatment with omalizumab. Despite this side effect, the patient continued with omalizumab treatment for 10 months with good effect.

U2 - 10.23822/EurAnnACI.1764-1489.08

DO - 10.23822/EurAnnACI.1764-1489.08

M3 - Journal article

C2 - 29249138

VL - 49

SP - 284

EP - 285

JO - European Annals of Allergy and Clinical Immunology

JF - European Annals of Allergy and Clinical Immunology

SN - 1764-1489

IS - 6

ER -

ID: 189622756